Skip to main content

Table 3 Risk of SPC by lung cancer histology after BC diagnosis (1993–2013)

From: Risk of second primary Cancer among bladder Cancer patients: a population-based cohort study in Korea

 

Latency (months)

 

Total

< 12

12–59

60–119

≥120

 

SIR (O/E)

95% CI

SIR (O/E)

SIR (O/E)

SIR (O/E)

SIR (O/E)

Lung, bronchus

1.05 (782/748.26)

(0.97–1.12)

0.98 (90/91.90)

1.07 (331/309.19)

1.03 (227/220.22)

1.06 (134/126.96)

Squamous cell carcinoma

1.15# (280/243.85)

(1.02–1.29)

0.94 (29/30.71)

1.18 (121/102.47)

1.08 (77/71.04)

1.34# (53/39.63)

Adenocarcinoma

1.20# (221/183.65)

(1.05–1.37)

1.39 (30/21.61)

1.27# (94/74.26)

1.15 (63/54.55)

1.02 (34/33.23)

Small cell carcinoma

1.06 (99/93.82)

(0.86–1.28)

0.69 (8/11.64)

1.10 (43/39.13)

1.13 (31/27.46)

1.09 (17/15.58)

Other and unspecified

0.80# (182/226.95)

(0.69–0.93)

0.82 (23/27.95)

0.78# (73/93.32)

0.83 (56/67.16)

0.78 (30/38.51)

  1. SPC: second primary cancer, BC: bladder cancer, SIR: standardized incidence ratio, CI: confidence interval, O/E: Observed/Expected
  2. # significant at alpha = 0.05